NEW YORK – Following a $6M Series A funding round earlier this month, Israeli personalized medicine company Curesponse will expand into the UK later this year by establishing a laboratory in London.
The Rehovot-based firm plans to launch clinical trials for its cResponse technology, which uses ex vivo organ culture (EVOC) to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs prior to treatment.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
